Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 37782 | 3.67 |
09:34 ET | 710 | 3.66 |
09:36 ET | 3400 | 3.645 |
09:38 ET | 2736 | 3.59 |
09:39 ET | 2005 | 3.6 |
09:41 ET | 9583 | 3.66 |
09:43 ET | 4458 | 3.68 |
09:45 ET | 600 | 3.66 |
09:50 ET | 1100 | 3.645 |
09:52 ET | 2919 | 3.69 |
09:54 ET | 1400 | 3.695 |
09:56 ET | 1291 | 3.725 |
09:57 ET | 829 | 3.725 |
09:59 ET | 1002 | 3.74 |
10:01 ET | 6593 | 3.69 |
10:03 ET | 4683 | 3.6915 |
10:06 ET | 400 | 3.705 |
10:08 ET | 3921 | 3.705 |
10:10 ET | 1200 | 3.745 |
10:12 ET | 1733 | 3.745 |
10:15 ET | 9300 | 3.75 |
10:17 ET | 300 | 3.75 |
10:21 ET | 15905 | 3.7102 |
10:24 ET | 330 | 3.71 |
10:26 ET | 3400 | 3.72 |
10:28 ET | 5306 | 3.73 |
10:30 ET | 1500 | 3.74 |
10:32 ET | 5919 | 3.735 |
10:33 ET | 3700 | 3.71 |
10:35 ET | 2584 | 3.72 |
10:37 ET | 1900 | 3.735 |
10:39 ET | 500 | 3.7305 |
10:42 ET | 7642 | 3.745 |
10:44 ET | 2372 | 3.725 |
10:46 ET | 420 | 3.7118 |
10:48 ET | 1440 | 3.725 |
10:50 ET | 100 | 3.725 |
10:51 ET | 800 | 3.725 |
10:53 ET | 587 | 3.7296 |
10:55 ET | 1171 | 3.75 |
10:57 ET | 1603 | 3.74 |
11:00 ET | 100 | 3.73 |
11:02 ET | 930 | 3.745 |
11:04 ET | 300 | 3.75 |
11:06 ET | 800 | 3.745 |
11:08 ET | 200 | 3.745 |
11:09 ET | 2479 | 3.745 |
11:11 ET | 8929 | 3.72 |
11:13 ET | 6483 | 3.74 |
11:15 ET | 300 | 3.735 |
11:18 ET | 1175 | 3.725 |
11:20 ET | 400 | 3.725 |
11:22 ET | 200 | 3.725 |
11:24 ET | 300 | 3.7201 |
11:26 ET | 722 | 3.725 |
11:27 ET | 2384 | 3.74 |
11:29 ET | 488 | 3.735 |
11:31 ET | 10896 | 3.7382 |
11:33 ET | 1800 | 3.745 |
11:36 ET | 100 | 3.745 |
11:38 ET | 6082 | 3.745 |
11:40 ET | 300 | 3.735 |
11:42 ET | 100 | 3.735 |
11:44 ET | 142 | 3.735 |
11:45 ET | 3701 | 3.75 |
11:47 ET | 558 | 3.755 |
11:49 ET | 500 | 3.7501 |
11:51 ET | 4032 | 3.745 |
11:54 ET | 1910 | 3.75 |
11:56 ET | 210 | 3.75 |
11:58 ET | 4362 | 3.755 |
12:00 ET | 1793 | 3.755 |
12:02 ET | 400 | 3.75 |
12:03 ET | 800 | 3.7511 |
12:05 ET | 500 | 3.755 |
12:07 ET | 7790 | 3.7601 |
12:09 ET | 100 | 3.7601 |
12:12 ET | 1600 | 3.78 |
12:14 ET | 2400 | 3.79 |
12:16 ET | 1981 | 3.785 |
12:18 ET | 600 | 3.785 |
12:20 ET | 647 | 3.785 |
12:21 ET | 5126 | 3.775 |
12:23 ET | 626 | 3.775 |
12:25 ET | 3900 | 3.77 |
12:27 ET | 100 | 3.77 |
12:30 ET | 41941 | 3.755 |
12:34 ET | 100 | 3.75 |
12:36 ET | 3632 | 3.77 |
12:38 ET | 1500 | 3.78 |
12:39 ET | 680 | 3.775 |
12:41 ET | 1554 | 3.79 |
12:43 ET | 300 | 3.785 |
12:45 ET | 1684 | 3.78 |
12:48 ET | 500 | 3.77 |
12:50 ET | 327 | 3.775 |
12:52 ET | 2200 | 3.77 |
12:54 ET | 2614 | 3.78 |
12:56 ET | 478 | 3.78 |
12:57 ET | 10151 | 3.805 |
12:59 ET | 711 | 3.805 |
01:01 ET | 8430 | 3.815 |
01:03 ET | 375 | 3.815 |
01:06 ET | 7477 | 3.83 |
01:08 ET | 1000 | 3.83 |
01:10 ET | 800 | 3.84 |
01:12 ET | 2200 | 3.8401 |
01:14 ET | 8910 | 3.85 |
01:15 ET | 7379 | 3.865 |
01:17 ET | 8960 | 3.855 |
01:19 ET | 558 | 3.855 |
01:24 ET | 1600 | 3.86 |
01:26 ET | 8359 | 3.845 |
01:28 ET | 527 | 3.85 |
01:30 ET | 66590 | 3.825 |
01:32 ET | 975 | 3.82 |
01:33 ET | 200 | 3.825 |
01:35 ET | 2530 | 3.825 |
01:37 ET | 6676 | 3.8419 |
01:39 ET | 3922 | 3.86 |
01:42 ET | 981 | 3.86 |
01:44 ET | 5091 | 3.865 |
01:46 ET | 1300 | 3.8517 |
01:48 ET | 100 | 3.855 |
01:50 ET | 424 | 3.855 |
01:51 ET | 100 | 3.86 |
01:53 ET | 1282 | 3.86 |
01:55 ET | 250 | 3.8591 |
01:57 ET | 1000 | 3.86 |
02:02 ET | 4792 | 3.845 |
02:04 ET | 10388 | 3.83 |
02:06 ET | 10043 | 3.84 |
02:08 ET | 525 | 3.84 |
02:09 ET | 100 | 3.84 |
02:13 ET | 300 | 3.85 |
02:15 ET | 1018 | 3.85 |
02:18 ET | 728 | 3.845 |
02:20 ET | 6679 | 3.82 |
02:22 ET | 9028 | 3.845 |
02:24 ET | 1100 | 3.85 |
02:26 ET | 175 | 3.855 |
02:27 ET | 100 | 3.86 |
02:29 ET | 5673 | 3.84 |
02:31 ET | 100 | 3.845 |
02:33 ET | 399 | 3.8414 |
02:36 ET | 5718 | 3.845 |
02:38 ET | 975 | 3.845 |
02:40 ET | 5423 | 3.86 |
02:42 ET | 1045 | 3.855 |
02:44 ET | 24882 | 3.855 |
02:45 ET | 1046 | 3.8501 |
02:47 ET | 600 | 3.85 |
02:49 ET | 100 | 3.855 |
02:51 ET | 100 | 3.855 |
02:54 ET | 100 | 3.855 |
02:56 ET | 5204 | 3.845 |
02:58 ET | 884 | 3.85 |
03:00 ET | 43561 | 3.8401 |
03:02 ET | 490 | 3.845 |
03:03 ET | 400 | 3.845 |
03:05 ET | 7223 | 3.825 |
03:07 ET | 1048 | 3.825 |
03:09 ET | 2343 | 3.835 |
03:14 ET | 11575 | 3.86 |
03:16 ET | 1754 | 3.87 |
03:18 ET | 2277 | 3.88 |
03:20 ET | 3900 | 3.89 |
03:21 ET | 4569 | 3.89 |
03:23 ET | 5046 | 3.895 |
03:25 ET | 2216 | 3.895 |
03:27 ET | 10280 | 3.885 |
03:30 ET | 745 | 3.885 |
03:32 ET | 2357 | 3.885 |
03:34 ET | 3680 | 3.885 |
03:36 ET | 2886 | 3.885 |
03:38 ET | 3023 | 3.89 |
03:39 ET | 18345 | 3.855 |
03:41 ET | 9249 | 3.84 |
03:43 ET | 5352 | 3.855 |
03:45 ET | 3959 | 3.865 |
03:48 ET | 5447 | 3.875 |
03:50 ET | 23865 | 3.85 |
03:52 ET | 2219 | 3.845 |
03:54 ET | 15535 | 3.855 |
03:56 ET | 40855 | 3.875 |
03:57 ET | 56311 | 3.88 |
03:59 ET | 388948 | 3.86 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 2.7B | -2.5x | --- |
MoonLake Immunotherapeutics | 2.7B | -55.7x | --- |
CG Oncology Inc | 2.7B | -38.4x | --- |
Apogee Therapeutics Inc | 2.7B | -27.1x | --- |
Janux Therapeutics Inc | 2.4B | -35.3x | --- |
Merus NV | 2.6B | -15.1x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 701.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.15 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.